Nair, Ramya
Salinas-Illarena, Alejandro
Sponheimer, Monika
Wullkopf, Inès
Schreiber, Yannick
Côrte-Real, João Vasco
del Pozo Ben, Augusto
Marterer, Helena
Thomas, Dominique
Geisslinger, Gerd
Cinatl, Jindrich Jr.
Subklewe, Marion
Baldauf, Hanna-Mari
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2020.097.1, 2020.097.1)
Studienstiftung des deutschen Volkes
Joachim Herz Foundation
Bavarian Elite Graduate School “i-target”
Fraunhofer Cluster of Excellence for Immune mediated Diseases
Fundação para a Ciência e Tecnologia (DFA/BD/4965/2020)
Deutsche Forschungsgemeinschaft (SFB-TRR 388/1 2021—452881907)
Ludwig-Maximilians-Universität München
Article History
Received: 4 April 2024
Accepted: 2 July 2024
First Online: 13 July 2024
Competing interests
: J.C. Jr. and H-M.B. are listed as inventors of patent no. WO2017076880A1. M.S. has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. M.S. sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers’ bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. M.S. declares patents together with Roche. All other authors declare no competing interests.
: BM samples were collected from patients with AML at primary diagnosis after written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-University (Munich, Germany, reference number: 216-08).